Videos

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Mohammad Ali Salehinejad, PhD, explains how template-based targeting could extend optimized multichannel tDCS to broader clinical and home-based care.

Oyvind Lie, MD, PhD, MSc, discusses the results from the ACASA-TAVI trial, which sought to evaluate the efficacy of anticoagulant monotherapy in this population.

Jose Nicolau, MD, PhD, discusses the results of his subanalysis of the VESALIUS-CV trial, examining secondary rather than first MACE.

A study found 4 mA multichannel tDCS achieved a 75% MDD response rate versus 45% for conventional 2 mA stimulation, Mohammad Ali Salehinejad, PhD, says.

Catch up on any stroke-related news you may have missed during 4 action-packed days of presentations and trial readouts at ESC 2026.

Research suggests wildfire smoke does more than irritate the airways in the moment; it may worsen allergic disease for months afterward.

David Oberlin, MD, on why trial enrichment, not mechanistic superiority, likely explains differing radiographic results in PsA drug trials.

A survey of patients with IgA nephropathy shows how nonspecific symptoms and long referral waits delay diagnosis by up to two years.

Catch up on data from some of the most impactful trials presented at the European Society of Cardiology Congress 2026.

Sharmila Dorbala, MD, MPH, discusses how this treatment and imaging strategy may lead to a diagnostic overhaul for patients with amyloidosis.

Rahul Aggarwal, MD, MBA, shares the results of his retrospective cohort study investigating the residual risk of heart failure after patients with prior MI.

Olivier Sitbon, MD, PhD, reviews PDGF-targeted therapy in PAH, from imatinib's IMPRES trial to new prodrug and antibody approaches.

Pooled data from 3 trials show H-ISDN cuts all-cause and cardiovascular death in HFrEF, though heterogeneity limits clinical impact.

Charalambos Antoniades, MD, PhD, discusses the recent trial investigating an AI-powered stroke and atrial fibrillation predictor.

Deepak Bhatt, MD, MPH, MBA, discusses the next steps for pacibekitug in cardiovascular disease following its success in the phase 2 trial.

A post hoc ALPACA analysis presented at ESC Congress 2026 shows lepodisiran cut Lp(a)-bound oxidized phospholipids by up to 94% at the 400-mg dose.

Deepak Bhatt, MD, MPH, MBA, discusses the efficacy of this investigational IL-6 antibody among patients at high inflammatory risk.

Hepatology in August 2026: FDA designations for volixibat and lonafarnib, ketogenic diet liver data, and alcohol use in CLD.

Radhika Shah, MD, explains why chronic hand eczema requires distinct diagnosis and treatment strategies, from topical limits to systemic therapy.

David T. Rubin, MD, on the questions, screening tools, and system barriers standing between IBD care and the whole patient.

Owen Muir, MD, calls accelerated SWIFT Deep TMS his personal first-line approach for active suicidal ideation, not an established guideline.

A secondary analysis found the SWIFT accelerated protocol eased suicidal ideation faster than standard daily deep TMS dosing in major depressive disorder.

Kristina Duffin, MD, MS, shares lessons from her LEADderm leadership session, including how to define which problems are truly yours to solve.

A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

Peter Lio, MD, discusses why precision medicine has advanced further in psoriasis than atopic dermatitis, and what oncology can teach dermatology.

Mahboobeh Mahdavinia, MD, says a published, safe at-home protocol for resolving egg allergy is rarely used because of the counseling time it demands.

Peter Lio, MD, on Skin Angels, a dermatology-focused angel-investing group that has evaluated over 300 companies and funded more than 30.